US Astute Imaging LLC Acquires Egyptian AI-based healthcare startup DilenyTech

DilenyTech, an Egyptian deep technology healthcare startup that is developing innovative artificial intelligence (AI) solutions for screening and diagnostic radiology workflow, has been acquired by Astute Imaging LLC of the United States.

DilenyTech, which was founded in 2018, aims to revolutionize breast cancer screening and diagnostic workflow by offering innovative AI-based assistance for more accurate detection and faster reporting.

The startup creates solutions for medical imaging analysis, breast cancer risk assessment, and structured reporting in a variety of medical applications, and has worked with top-tier international health-tech companies on three continents.

DilenyTech, which received $160,000 in grant funding last year, has been acquired by Astute Imaging, a provider of imaging guided therapy and procedure planning services. Astute Imaging will be able to use the power of AI to improve its current offering, expand services, and develop innovative solutions in the medical imaging domain as a result of the acquisition.

“Astute Imaging will be able to accelerate the development of an AI-driven image-guided therapy platform and add more automation to our imaging services and procedure planning solutions as a result of this strategic acquisition of DilenyTech,” said Wael Elseaidy, co-founder and CEO of Astute Imaging. “By incorporating AI into our surgery planning and patient follow-up imaging platforms, we will be able to provide more patient-centric proactive services to our customers and medical imaging stakeholders.”

“We are thrilled to be a part of Astute Imaging’s incredible team and to apply our expertise and technologies to the development of reliable AI technologies for imaging-guided therapy,” said Ahmed Ehab Mahmoud, DilenyTech founder and innovation director, who will join Astute Imaging’s founding team and manage imaging operations.

“We have successfully applied our technologies in breast imaging, and we look forward to expanding our AI pipeline to other imaging areas such as thyroid, liver, and gynecology, as well as cardiovascular 3D imaging and procedural planning.” Astute Imaging, we believe, will be a game changer for healthcare providers and device companies.”